Esuberaprost - Lung Biotechnology

Drug Profile

Esuberaprost - Lung Biotechnology

Alternative Names: 314d; APS-314d; Beraprost Sodium 314d Modified Release; Beraprost-314d; BPS-314d-MR; L-314d-QID

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toray
  • Developer Lung Biotechnology
  • Class 3-ring heterocyclic compounds; Alkynes; Antihypertensives; Antiplatelets; Benzofurans; Butyric acids; Cardiovascular therapies; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension

Most Recent Events

  • 18 May 2018 Efficacy, adverse events and pharmacokinetics data from a phase I trial in healthy volunteers presented at 114th International Conference of the American Thoracic Society (ATC-2018)
  • 27 Sep 2017 Esuberaprost is still in phase III trials for Pulmonary arterial hypertension in USA and Israel (NCT01908699)
  • 27 Jul 2017 United Therapeutics completes enrolment in a phase-III clinical trial in Pulmonary arterial hypertension in USA prior to July 2017 (PO) (NCT01908699; 9220286)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top